Erratum: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716))

P. Y. Kwo, E. J. Lawitz, J. McCone

Research output: Contribution to journalComment/debate

4 Scopus citations
Original languageEnglish (US)
Number of pages1
JournalThe Lancet
Issue number9748
StatePublished - Oct 9 2010

ASJC Scopus subject areas

  • Medicine(all)

Cite this